International Congress of DAO Deficiency 2021
You are invited to map a new future in managing DAO Deficiency attending the International Congress on DAO Deficiency.
SAVE THE DATE: November 4th 2021
At DR HEALTHCARE, we are pioneers in DAO Deficiency. Since our beginnings, scientific evidence and research have driven each one of our steps. The time has come to share this knowledge with the scientific and medical community, nutrition specialists, and patients who suffer from this metabolic deficiency’s different recurring symptoms.
Together, we can go farther.
Which is why we are delighted to invite you to the International Congress of DAO Deficiency, to be held 4 November 2021, in virtual format.
Our end goal:
is to reinforce knowledge of DAO Deficiency through a complete programme of scientific sessions, with experts of worldwide renown. With a forward-looking approach, we will address both diagnosis and treatment, as well as how knowledge of DAO Deficiency has led to a paradigm shift in the field of medical nutrition.
The event will be held entirely online:
as required by this exceptional situation caused by the pandemic. However, this way we will also be able to make our shared knowledge and experiences available to professionals all around the world, saving on costs and travel, and reducing our ecological footprint.
Technology will make it possible:
for guests to attend all conferences through an immersive, comprehensive experience. In addition to the extensive medical and scientific programme, the exhibition with 3D stands, and online interaction with guests, congress participants and speakers will provide a one-of-a-kind stage with services just like at a face-to-face event. All in real time.
We eagerly await you.
Warm regards,
Gerald Dard Juanjo Duelo
Managing Director ABBiotek Global Business Development Director Enzymes
AB Biotek Acquires Spanish Biomedical DR Healthcare
Respective leaders in fermentation science and DAO-based medical nutrition join together to focus on innovative enzyme-based solutions for the human nutrition & health market.
PETERBOROUGH, U.K. 26 may 2021 – AB Biotek, a global business division of Associated British Foods plc – today announces that it has acquired DR Healthcare, a biomedical company focused on the dietary management of chronic diseases based in Barcelona, Spain.
This acquisition enables AB Biotek to boost its growing portfolio of differentiated microbiome modulating solutions for human nutrition and health. The acquisition adds diamine oxidase (DAO), an important intestinal enzyme, that will expand AB Biotek’s already strong commercial portfolio of probiotic yeast strains.
DAO, naturally secreted by the human body, is widely known as a critical enzyme at the core of reducing symptoms of many of today’s ailments, including migraine, food intolerances and attention deficit hyperactivity disorder, prevalent in millions of people around the world.
Juanjo Duelo, the founder of DR Healthcare, will remain with the business.
“With the acquisition of DR Healthcare, we now have the next stepping stone in shaping our science-based organization to serve the fast-growing human nutrition and health space,” said Gerald Dard, global managing director, AB Biotek. “DR Healthcare has a strong track record in this area, and we welcome our new colleagues who are equally passionate about the health and wellness of today’s consumers.”
“I am very excited about this new chapter as our companies have many shared values, from advanced health solutions and deep science to an extreme passion for what we do,” said Juanjo Duelo. “The future is bright under the good ownership of AB Biotek, and the timing is perfect to bring new, innovative technologies to improve the wellbeing of those people who suffer from various pathologies associated with the deficiency of DAO.”
About AB Biotek
AB Biotek contributes to the success of customers through the delivery of customized fermentation-based, sustainable solutions containing proprietary and/or purposefully sourced microorganisms to created differentiated food, beverage, health & nutrition business opportunities. Science and advanced microorganism fermentation technology are core enablers. AB Biotek has commercial scale production and research development facilities located around the world. For more information about our product applications and unmatched technical service capabilities, please visit www.abbiotek.com.
About DR Healthcare
Founded in Barcelona, Spain, in 2007, DR Healthcare is a biomedical company specialized in medical nutrition and dedicated to the research, development, innovation, marketing and licensing of new nutraceuticals, functional foods, active ingredients and customized solutions. Our medical nutrition products are aimed at dietary management of chronic diseases, physiological dysfunctions and/or metabolic diseases, mainly associated with metabolic disorders caused by a deficiency of the intestinal enzyme diamine oxidase (DAO). DR Healthcare produces DAO for both human and animal use and offers proprietary solutions for the food, pharmaceutical, veterinary and animal health industries. More information is available at www.dr-healthcare.com/en.
Patrick Barry +1.314.540.3865
LLYC
Tina Díaz adiaz@llorenteycuenca.com
Míriam Cusí mcusi@llorenteycuenca.com
Cristina Vilà cvila@llorenteycuenca.com
Association of Diamine oxidase (DAO) variants with the risk for migraine from North Indian population
Association of Diamine oxidase (DAO) variants with the risk for migraine from North Indian population
Sukhvinder Kaura,⁎, Arif Alib, Yaser Siahbalaeic, Uzair Ahmadc, Fazila Nargisc, A.K. Pandeyd,
Balkirat Singhe
a UGC-PDF, Gene Expression Lab, Department of Biosciences, Jamia Millia Islamia, New Delhi, India
b UGC-BSR-FF, Department of Biosciences, Jamia Millia Islamia, New Delhi, India
c Department of Biosciences, Jamia Millia Islamia, New Delhi, India
d Head, Department of Physiology, ESIC Medical College & Hospital, Faridabad, India
e NC Medical College & Hospital, Panipat, India
A B S T R A C T
Background: Migraine is a common neurovascular disorder affected by various levels of neurotransmitters. Low histamine metabolism is also related with pathophysiology of migraine. As diamine oxidase (DAO) gene variants are linked with higher levels of histamine in migraine patients, we investigated the possible relationship of two variants rs2052129 and rs10156191of this gene with migraine risk in North Indian population.
Methods: A case-control study for 250 migraine patients and 250 matched healthy controls was conducted by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Results: We found statistically significant differences in allelic frequencies of rs2052129 (p = .009, OR = 1.462; 95% CI: 1.098–1.947) and rs10156191 (p = .019, OR = 1.430; 95% CI: 1.060–1.928) variants in DAO gene. For rs1015691, we were able to show statistically significant association at all genotypic, dominant and allelic levels in both MA (for T allele, p = .020; OR = 1.662, 95% CI: 1.083–2.551) as well as in female subgroup (for T allele, p = .025, OR = 1.460; 95% CI: 1.049–2.033). But no such significant association was found in clinical sub grouping of migraine in rs2052129 as p > .05. However in gender analysis, protective effect of T allele in male migraine patients for rs2052129 (OR < 1) was found.
Conclusions: Our findings clearly indicated that female patient with rs10156191T allele and in MA subgroup showed an increased risk for migraine. Our data also indicated that rs2052129T variant showed a significant role in migraine susceptibility of this population.
Conformational Design and Characterisation of a Truncated Diamine Oxidase from Arthrobacter globiformis
Conformational Design and Characterisation of a Truncated Diamine Oxidase from Arthrobacter globiformis
Download pdf
Abstract
A functional mini protein can be developed by miniaturising its size. The minimisation technique provides an excellent model system for studying native enzymes, especially in creating an alternative novel biocatalyst. Miniaturised proteins may have enhanced stability, a crucial characteristic for large-scale production and industrial applications. In this study, a huge enzyme molecule, known as diamine oxidase (DAO, comprising 700 amino acids), was selected to undergo the process.
Methods
Results
Pregnancy-associated diamine oxidase originates from extravillous trophoblasts and is decreased in early-onset preeclampsia
Pregnancy-associated diamine oxidase originates from extravillous trophoblasts and is decreased in early-onset preeclampsia
Download pdf
Sci Rep. 2018 Apr 20;8(1):6342. doi: 10.1038/s41598-018-24652-0.
Author information
- 1
- Department of Obstetrics and Gynaecology, Reproductive Biology Unit, Medical University of Vienna, Vienna, Austria.
- 2
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
- 3
- Department of Obstetrics and Gynaecology, Division of General Gynaecology and Gynaecologic Oncology, Medical University of Vienna, Vienna, Austria.
- 4
- Forensic Toxicology, Clinical Institute of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
- 5
- Children’s Cancer Research Institute, Vienna, Austria.
- 6
- Section for Medical Statistics (IMS), Center of Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
- 7
- Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.
- 8
- Gynmed Clinic, Vienna, Austria.
- 9
- Division of Maternal and Fetal Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States.
- 10
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. thomas.boehm@meduniwien.ac.at.
- 11
- Department of Obstetrics and Gynaecology, Reproductive Biology Unit, Medical University of Vienna, Vienna, Austria. juergen.pollheimer@meduniwien.ac.at.
Abstract
Human extravillous trophoblast (EVT) invasion of the pregnant uterus constitutes a pivotal event for the establishment of the maternal-fetal interface. Compromised EVT function manifesting in inadequate arterial remodeling is associated with the severe pregnancy disorder early-onset preeclampsia (eoPE).
Recent studies suggest that EVTs invade the entire uterine vasculature including arteries, veins and lymphatics in the first trimester of pregnancy. We therefore hypothesized that EVT-derived factors accumulate in the circulation of pregnant women early in gestation and may serve to predict eoPE.
In contrast to published literature, we demonstrate that placenta-associated diamine oxidase(DAO) is not expressed by maternal decidual cells but solely by EVTs, especially when in close proximity to decidual vessels.
Cultures of primary EVTs express and secret large amounts of bioactive DAO.
ELISA measurements indicate a pregnancy-specific rise in maternal DAO plasma levels around gestational week (GW) 7 coinciding with vascular invasion of EVTs.
Strikingly, DAO levels from eoPE cases were significantly lower (40%) compared to controls in the first trimester of pregnancy but revealed no difference at mid gestation. Furthermore, DAO-containing pregnancy plasma rapidly inactivates pathophysiologically relevant histamine levels.
This study represents the first proof of concept suggesting EVT-specific signatures as diagnostic targets for the prediction of eoPE.
- PMID: 29679053
- PMCID: PMC5910386
- DOI: 10.1038/s41598-018-24652-0
Mapping of the binding sites of human diamine oxidase (DAO) monoclonal antibodies
Mapping of the binding sites of human diamine oxidase (DAO) monoclonal antibodies
Download pdf
Author information
- 1 Department of Visceral, Transplant and Thoracic Surgery, Molecular Biology Laboratory, Medical University Innsbruck, Schöpfstraße 41, 6020, Innsbruck, Austria. hubert.schwelberger@i-med.ac.at.
- 2 Department of Visceral, Transplant and Thoracic Surgery, Molecular Biology Laboratory, Medical University Innsbruck, Schöpfstraße 41, 6020, Innsbruck, Austria.
- 3 Department of Autoimmunology and Biomarkers, Statens Serum Institut, Artillerivej 5, 2300, Copenhagen, Denmark.
Abstract
OBJECTIVE:
Recently we characterized five mouse monoclonal antibodies that allow the specific and sensitive detection of human diamine oxidase (DAO). To understand differences in binding characteristics and recognition of enzyme variants, we mapped the antibody binding sites.
METHODS:
Fragments of human DAO were expressed as glutathione-S-transferase fusion proteins that were used for testing antibody binding on immunoblots. Combined information from species cross-reactivity, sequence comparison and binding site-prediction software were used to localize the epitope recognized by each antibody.
RESULTS:
All five monoclonal DAO antibodies bound to linear epitopes between the N3 and enzymatic domains of the 732 amino acid protein. The binding sites could be mapped onto amino acid regions V262-E278 and P279-R288, respectively, which exhibit considerable sequence variation in mammals explaining the fact that the human DAO antibodies do not cross-react with DAO from other species. The antibodies efficiently bind only denatured human DAO but not the native protein.
CONCLUSIONS:
Characterization of the binding sites of the DAO antibodies revealed that the antibodies bind two adjacent epitopes and exhibit similar binding characteristics and species cross-reactivity. As the epitopes do not overlap any of the amino acid substitutions described for clinically significant DAO gene polymorphisms, our antibodies will also be useful for analyses of the mutant DAO proteins.
KEYWORDS:
Diamine oxidase; Epitope mapping; Histamine metabolism; Monoclonal antibodies; Protein expression
- PMID: 29164268
- PMCID: PMC5807474
- DOI: 10.1007/s00011-017-1118-3
Progress on the deficit of the enzyme DAO
Read the original article in LA VANGUARDIA
New research led by Dr. Ramon Tormo, Chief of Gastroenterology and Nutrition Hospital Chiron Barcelona, attributed migraine to reaffirm deficit DAO enzyme.
Plasma diamine oxidase activity is a useful biomarker for evaluating gastrointestinal tract toxicities during chemotherapy with oral fluorouracil anti-cancer drugs in patients with gastric cancer.
Plasma diamine oxidase activity is a useful biomarker for evaluating gastrointestinal tract toxicities during chemotherapy with oral fluorouracil anti-cancer drugs in patients with gastric cancer.
Download pdf
Author information
- 1 Department of Surgery, Kochi Medical School, Nankoku, Japan. tsutomun@kochi-u.ac.jp
Abstract
OBJECTIVES:
Diamine oxidase (DAO) is an enzyme that catalyzes oxidation and is highly active in the mature upper villus cells of the intestinal mucosa. This study sought to evaluate plasma DAO activities during adjuvant chemotherapy in patients with gastric cancer.
METHODS:
We investigated 20 patients with gastric cancer who were treated with oral fluorouracil anti-cancer drugs as adjuvant chemotherapy. Plasma DAO activity was measured in all patients before chemotherapy and at 2, 4 and 6 weeks after the start of chemotherapy, and quality of life was evaluated simultaneously.
RESULTS:
The median DAO activity after 4 weeks of chemotherapy was significantly decreased compared to the pre-chemotherapy levels (6.6 vs. 7.5 U/l; p = 0.038). The changes in the rate of DAO activity at 2 and 6 weeks following the start of chemotherapy in patients with gastrointestinal tract toxicity were significantly lower than in those without toxicity (p =0.021 and 0.047, respectively). The patient cohort showed a slightly positive correlation between DAO activity and global health status and a negative correlation between DAO activity and appetite loss.
CONCLUSIONS:
Plasma DAO activities may be useful for monitoring and evaluating gastrointestinal tract toxicities induced by adjuvant chemotherapy with oral fluorouracil in patients with gastric cancer.
Copyright © 2012 S. Karger AG, Basel.
- PMID: 22433290
- DOI: 10.1159/000336799